About Us
FDA Roadmap to Reducing Animal Testing: A New Regulatory Era
News
Author
biospero
Date
2025-07-21 11:26
Views
985
FDA Roadmap to Reducing Animal Testing: A New Regulatory Era
By Brian Ogilvie, PhD, Vice President of Scientific Consulting / July 9, 2025
In April 2025, the FDA unveiled a transformative Roadmap to Reducing Animal Testing in Preclinical Safety Studies, outlining a 3–5 year ambition to make animal studies the exception rather than the rule. This initiative builds on the 2022 FDA Modernization Act 2.0, which legally removed the requirement for animal testing in IND and BLA submissions. FDA Commissioner, Martin Makary, emphasized its potential, saying, “This initiative marks a paradigm shift in drug evaluation … while reducing animal use,” aiming to accelerate cures and treatments (FDA).
Hesperos, a developer of organ-on-chip systems, commented, “This exciting announcement outlines a 3-year strategic roadmap for implementing the use of New Approach Methodologies (NAMs) and represents a significant step forward in gaining widespread regulatory adoption. This is the product of a long-standing, collective effort from government, advocacy groups, and industry marking a significant shift into a new chapter for drug discovery” (Hesperos).
Core Elements of the Roadmap
Initial Focus on monoclonal antibodies: MAb developers are invited to participate in pilot programs that rely primarily on NAMs instead of traditional animal toxicity studies.
Integration of NAMs: leveraging organ-on-chip systems, human tissue assays, in silico PBPK modeling, AI-driven immunogenicity predictors, and microdosing with PET imaging in humans as substitutes for animal data.
Regulatory Adaptations: introducing formal guidances, waivers, and fast-tracking for applications built largely on NAM-supported data.
Evidence Tracking: the FDA will monitor usage of NAMs vs. animals, cost per IND, and predictive accuracy, publishing findings publicly.
Interagency Collaboration: ICCVAM (NIH, EPA, and VA participation) will coordinate validation and global harmonization of NAMs (FDA).
Regulators and researchers alike recognize the need to move towards more human-relevant testing. NAMs aim to provide more accurate preclinical drug safety and efficacy data, and in doing so, also eliminate the financial and ethical burdens of unnecessary animal testing. A Johns Hopkins policy blog observation notes, “Studies indicate that over 90% of drugs that appear safe and effective in animals fail during human clinical trials … Over time, the roadmap envisions making animal studies the exception rather than the rule in preclinical drug development. This is a welcome move.” (Johns Hopkins).
However, validating the superiority of NAMs is a critical component of the program’s success. Axion BioSystems, a manufacturer of next-generation lab tools, commented, “Demonstrating the scientific validity and reliability of NAMs is crucial. Sponsors should provide robust data to support the use of these methodologies in their specific context.” They further recommended, “Sponsors are encouraged to engage with the FDA early in the development process to discuss the integration of NAMs into their testing strategies and to ensure alignment with regulatory expectations.” (Axion Biosystems).
Drug developers who utilizescientifically validated NAMs may then see benefits in the regulatory review process. Reutersreported that “companies that submit strong safety data from non-animal tests may receive a streamlined review” (Reuters).
These incentives are expected to fuel further investment in NAMs, accelerating the significant progress that has already been made. Increasing utilization of AI in medical research is also anticipated to benefit the utilization of NAMs, particularly in the modeling arena. Schrödinger CEO, Ramy Farid, said, “The role of computational methods is changing rapidly in the pharmaceutical industry, and it is exciting to see these methods recognized as a powerful solution for optimizing drug candidates for both efficacy and safety,” (Schrödinger). Simulations Plusstated, “The FDA’s roadmap sends a clear signal that the future of preclinical safety assessment lies in innovative, non-animal methodologies, and modeling and simulation will be central to that shift” (BioSpace).
NAMs in Detail: FDA-Supported Methodologies
The roadmap identifies five core NAM types:
How BioIVT Biospecimens & Services Facilitate NAM Development
BioIVT has been at the forefront of providing resources currently being used for NAM submissions and offers a suite of human-derived biospecimens and services that are aligned with the FDA's vision to assist your research:
Human Tissues for Microphysiological Systems: fresh/frozen tissues (e.g., liver, lung, tumor biopsies) to seed organ-on-a-chip systems.
Disease-State Biospecimen Cohorts: panels from neurologic, oncology, and autoimmune patients provide pathological diversity, critical to assess off-target toxicities across populations in in vitro models.
ADME & Biospecimen Products: blood, serum, plasma, ADME-Tox reagents for PK modeling and in vitro assays, bolstering PBPK inputs or ex vivo exposures.
Cell Products (PBMCs, Leukopaks): cryopreserved leukopaks support immune assays such as cytokine release panels, complementing human-specific immunogenicity testing in NAMs.
Analytical & Regulatory Services: from tissue procurement oversight to regulatory-compliant chains of custody and submission-ready data, BioIVT ensures suitability for FDA submission.
Integrative NAM Use Cases with BioIVT
Key Takeaways & Strategic Guidance
The Regulatory Landscape Is Shifting Rapidly: The FDA’s roadmap marks both a legal and cultural transformation of preclinical safety as a hybrid framework where NAMs are no longer simply optional, but desirable and incentivized.
NAMs Offer Scientific, Ethical, and Economic Upsides: They are more human-relevant, reduce animal use, and may lower costs and decrease time to market.
Practical Execution Requires High-Quality Human Specimens: Reliable organ chips, tissue arrays, and immune assays depend on well-characterized human biospecimens, which BioIVT offers.
Sponsors Must Collaborate Proactively with FDA: Pilot programs offer clear paths, but early and transparent engagement is crucial to validate NAM study designs aligned with regulatory expectations.
Final Thoughts
The FDA’s roadmap represents one of the most definitive regulatory shifts toward human-centric science and ethical responsibility in drug development. With federal agencies, software providers, and patient advocates on board, the era of “animal studies first” will eventually become “human data first.” As this change occurs, organizations like BioIVT, offering high-quality biospecimens, assays, and regulatory-ready frameworks, are pivotal enablers of NAM development and subsequent adoption. Sponsors that embrace NAM-ready strategies today position themselves for safer drugs, reduced animal use, and streamlined approvals.
BioIVT has been leading the way with the broadest offering of biospecimens and a global network to suit your needs.
By Brian Ogilvie, PhD, Vice President of Scientific Consulting / July 9, 2025
In April 2025, the FDA unveiled a transformative Roadmap to Reducing Animal Testing in Preclinical Safety Studies, outlining a 3–5 year ambition to make animal studies the exception rather than the rule. This initiative builds on the 2022 FDA Modernization Act 2.0, which legally removed the requirement for animal testing in IND and BLA submissions. FDA Commissioner, Martin Makary, emphasized its potential, saying, “This initiative marks a paradigm shift in drug evaluation … while reducing animal use,” aiming to accelerate cures and treatments (FDA).
Hesperos, a developer of organ-on-chip systems, commented, “This exciting announcement outlines a 3-year strategic roadmap for implementing the use of New Approach Methodologies (NAMs) and represents a significant step forward in gaining widespread regulatory adoption. This is the product of a long-standing, collective effort from government, advocacy groups, and industry marking a significant shift into a new chapter for drug discovery” (Hesperos).
Core Elements of the Roadmap
Initial Focus on monoclonal antibodies: MAb developers are invited to participate in pilot programs that rely primarily on NAMs instead of traditional animal toxicity studies.
Integration of NAMs: leveraging organ-on-chip systems, human tissue assays, in silico PBPK modeling, AI-driven immunogenicity predictors, and microdosing with PET imaging in humans as substitutes for animal data.
Regulatory Adaptations: introducing formal guidances, waivers, and fast-tracking for applications built largely on NAM-supported data.
Evidence Tracking: the FDA will monitor usage of NAMs vs. animals, cost per IND, and predictive accuracy, publishing findings publicly.
Interagency Collaboration: ICCVAM (NIH, EPA, and VA participation) will coordinate validation and global harmonization of NAMs (FDA).
Regulators and researchers alike recognize the need to move towards more human-relevant testing. NAMs aim to provide more accurate preclinical drug safety and efficacy data, and in doing so, also eliminate the financial and ethical burdens of unnecessary animal testing. A Johns Hopkins policy blog observation notes, “Studies indicate that over 90% of drugs that appear safe and effective in animals fail during human clinical trials … Over time, the roadmap envisions making animal studies the exception rather than the rule in preclinical drug development. This is a welcome move.” (Johns Hopkins).
However, validating the superiority of NAMs is a critical component of the program’s success. Axion BioSystems, a manufacturer of next-generation lab tools, commented, “Demonstrating the scientific validity and reliability of NAMs is crucial. Sponsors should provide robust data to support the use of these methodologies in their specific context.” They further recommended, “Sponsors are encouraged to engage with the FDA early in the development process to discuss the integration of NAMs into their testing strategies and to ensure alignment with regulatory expectations.” (Axion Biosystems).
Drug developers who utilizescientifically validated NAMs may then see benefits in the regulatory review process. Reutersreported that “companies that submit strong safety data from non-animal tests may receive a streamlined review” (Reuters).
These incentives are expected to fuel further investment in NAMs, accelerating the significant progress that has already been made. Increasing utilization of AI in medical research is also anticipated to benefit the utilization of NAMs, particularly in the modeling arena. Schrödinger CEO, Ramy Farid, said, “The role of computational methods is changing rapidly in the pharmaceutical industry, and it is exciting to see these methods recognized as a powerful solution for optimizing drug candidates for both efficacy and safety,” (Schrödinger). Simulations Plusstated, “The FDA’s roadmap sends a clear signal that the future of preclinical safety assessment lies in innovative, non-animal methodologies, and modeling and simulation will be central to that shift” (BioSpace).
NAMs in Detail: FDA-Supported Methodologies
The roadmap identifies five core NAM types:
How BioIVT Biospecimens & Services Facilitate NAM Development
BioIVT has been at the forefront of providing resources currently being used for NAM submissions and offers a suite of human-derived biospecimens and services that are aligned with the FDA's vision to assist your research:
Human Tissues for Microphysiological Systems: fresh/frozen tissues (e.g., liver, lung, tumor biopsies) to seed organ-on-a-chip systems.
Disease-State Biospecimen Cohorts: panels from neurologic, oncology, and autoimmune patients provide pathological diversity, critical to assess off-target toxicities across populations in in vitro models.
ADME & Biospecimen Products: blood, serum, plasma, ADME-Tox reagents for PK modeling and in vitro assays, bolstering PBPK inputs or ex vivo exposures.
Cell Products (PBMCs, Leukopaks): cryopreserved leukopaks support immune assays such as cytokine release panels, complementing human-specific immunogenicity testing in NAMs.
Analytical & Regulatory Services: from tissue procurement oversight to regulatory-compliant chains of custody and submission-ready data, BioIVT ensures suitability for FDA submission.
Integrative NAM Use Cases with BioIVT
Key Takeaways & Strategic Guidance
The Regulatory Landscape Is Shifting Rapidly: The FDA’s roadmap marks both a legal and cultural transformation of preclinical safety as a hybrid framework where NAMs are no longer simply optional, but desirable and incentivized.
NAMs Offer Scientific, Ethical, and Economic Upsides: They are more human-relevant, reduce animal use, and may lower costs and decrease time to market.
Practical Execution Requires High-Quality Human Specimens: Reliable organ chips, tissue arrays, and immune assays depend on well-characterized human biospecimens, which BioIVT offers.
Sponsors Must Collaborate Proactively with FDA: Pilot programs offer clear paths, but early and transparent engagement is crucial to validate NAM study designs aligned with regulatory expectations.
Final Thoughts
The FDA’s roadmap represents one of the most definitive regulatory shifts toward human-centric science and ethical responsibility in drug development. With federal agencies, software providers, and patient advocates on board, the era of “animal studies first” will eventually become “human data first.” As this change occurs, organizations like BioIVT, offering high-quality biospecimens, assays, and regulatory-ready frameworks, are pivotal enablers of NAM development and subsequent adoption. Sponsors that embrace NAM-ready strategies today position themselves for safer drugs, reduced animal use, and streamlined approvals.
BioIVT has been leading the way with the broadest offering of biospecimens and a global network to suit your needs.
Total 0